Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea

Authors Koo HL, DuPont HL, Huang D

Published 21 October 2009 Volume 2009:5 Pages 841—848

DOI https://doi.org/10.2147/TCRM.S4442

Review by Single-blind

Peer reviewer comments 3


Hoonmo L Koo1,2, Herbert L DuPont1,2, David B Huang3

1Baylor College of Medicine, Houston, TX, USA; 2University of Texas at Houston School of Public Health, Houston, TX, USA; 3Veterans Affairs Medical Center, East Orange, NJ, USA

Abstract: Travelers’ diarrhea is a common illness among international travelers from developed to developing countries. Travelers’ diarrhea is caused by ingestion of contaminated food and water. Bacteria are the primary cause of travelers’ diarrhea. In most surveys, the most common diarrheal pathogen identified is enterotoxigenic Escherichia coli. There are several antimicrobial agents available for the treatment of travelers’ diarrhea including rifaximin which is approved in the United States for the treatment of travelers’ diarrhea due to noninvasive E. coli strains. In this review, we will review the most recent advances of rifaximin for the treatment and prevention of travelers’ diarrhea, with regard to its pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials.

Keywords: travelers’ diarrhea, rifaximin, treatment, prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]